FDA wants advisers' recommendation on Trilipix-statin combo

05/16/2011 | Reuters

The FDA will ask an advisory committee Thursday whether marketing approval should be revoked for Trilipix, a heart drug by Abbott Laboratories, to be used with a statin. Advisers are also expected to deliberate whether Trilipix's label should state that the combination of a similar medicine, TriCor, and a statin did not reduce cardiovascular risk in women during the Accord-Lipid trial.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ